Egetis Therapeutics
Develops and commercializes treatments for serious and rare diseases.
EGTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Manufacturing
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-30 08:00 |
Ändring av antalet stamaktier och röster i Egetis Therapeutics
|
Swedish | PDF • 61.2 KB | ||
| 2025-12-30 08:00 |
Change in the number of ordinary shares and votes in Egetis Therapeutics
|
English | PDF • 57.7 KB | ||
| 2025-12-19 07:00 |
Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (ti…
|
English | PDF • 79.4 KB | ||
| 2025-12-19 07:00 |
Egetis Therapeutics inleder NDA ansökan i USA för Emcitate® (tiratricol) vid MC…
|
Swedish | PDF • 78.9 KB | ||
| 2025-11-25 07:00 | Swedish | PDF • 761.2 KB | |||
| 2025-11-25 07:00 | English | PDF • 736.4 KB | |||
| 2025-11-14 07:00 |
Egetis meddelar positiva resultat från ReTRIACt-studien med Emcitate® (tiratric…
|
Swedish | PDF • 84.6 KB | ||
| 2025-11-14 07:00 |
Egetis announces positive results from the ReTRIACt study of Emcitate® (tiratri…
|
English | PDF • 82.0 KB | ||
| 2025-10-31 08:00 |
Change in the number of shares and votes in Egetis Therapeutics
|
English | PDF • 58.2 KB | ||
| 2025-10-31 08:00 |
Ändring av antalet aktier och röster i Egetis Therapeutics
|
Swedish | PDF • 61.4 KB | ||
| 2025-10-23 08:00 |
Egetis beviljas löpande NDA-granskning av FDA för Emcitate® (tiratricol) basera…
|
Swedish | PDF • 90.0 KB | ||
| 2025-10-23 08:00 |
Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on …
|
English | PDF • 86.3 KB | ||
| 2025-10-02 23:40 |
Egetis Therapeutics has successfully carried out a directed share issue amounti…
|
English | PDF • 82.9 KB | ||
| 2025-10-02 23:40 |
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående …
|
Swedish | PDF • 83.7 KB | ||
| 2025-10-02 17:31 |
Egetis Therapeutics intends to carry out a directed share issue of up to 10 per…
|
English | PDF • 76.8 KB |
Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Egetis Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-09 | Yilmaz Mahshid | Other | Sell | 39,753 | 268,332.75 SEK |
| 2025-01-08 | Yilmaz Mahshid | Other | Sell | 98,567 | 653,499.21 SEK |
| 2025-01-07 | Yilmaz Mahshid | Other | Sell | 74,769 | 507,681.51 SEK |
| 2024-10-07 | Nicklas Westerholm | Other | Buy | 10,142 | 43,103.50 SEK |
| 2024-10-07 | Yilmaz Mahshid | Other | Buy | 10,000 | 42,250.00 SEK |
| 2023-07-07 | Henrik Krook | Other | Buy | 33,594 | 133,704.12 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 3,616 | 14,391.68 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 2,000 | 7,920.00 SEK |
| 2023-07-05 | Christian Sonesson | Other | Buy | 1,384 | 5,452.96 SEK |
| 2023-07-04 | Nicklas Westerholm | Other | Buy | 15,350 | 60,632.50 SEK |
Peer Companies
